Business Context and Reporting Period
Unicycive Therapeutics, Inc. (UNCY), a Delaware corporation, filed this Form 8-K on July 9, 2024. The company is an emerging growth company with its principal executive offices in Los Altos, California. The filing addresses a regulatory notice received from the Nasdaq Stock Market regarding the continued listing of its common stock.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on a listing compliance issue.
Material Changes
The material event reported is the receipt of a written notice from Nasdaq on July 9, 2024. The notice states that the company's common stock closed below the minimum $1.00 per share bid price requirement for 30 consecutive business days, resulting in non-compliance with Nasdaq Listing Rule 5550(a)(2). The stock continues to trade on the Nasdaq Capital Market under the symbol "UNCY" pending compliance actions.
Outlook, Risks, and Management Commentary
- Compliance Period: The company has 180 calendar days, until January 6, 2025, to regain compliance.
- Compliance Criteria: To regain compliance, the closing bid price must meet or exceed $1.00 per share for a minimum of ten consecutive business days within the 180-day window.
- Delisting Risk: If compliance is not achieved by January 6, 2025, the company may qualify for a second 180-day period. Failure to regain compliance during the second period could result in a delisting determination, which the company could appeal to a Nasdaq hearings panel.
- Management Action: Management intends to actively monitor the stock price and may consider implementing available options to regain compliance.
Investor Verification Checklist
- Verify the current closing bid price of UNCY stock relative to the $1.00 threshold.
- Monitor the company's stock price for ten consecutive days of trading at or above $1.00 before the January 6, 2025 deadline.
- Review future filings for any announcements regarding reverse stock splits or other corporate actions intended to address the bid price deficiency.
- Check for any subsequent notices from Nasdaq regarding the status of the compliance period or potential delisting determinations.